Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Nomination Summary for Hydrochlorothiazide/UV light (solar simulated light) (N21307)

Nominated Substances: Hydrochlorothiazide

Nomination Date: 08/12/2013

Nominator: Private Individual

Rationale: Hydrochlorothiazide is a widely used diuretic used to treat hypertension, congestive heart failure, and other fluid retention disorders. Although human epidemiology studies have associated hydrochlorothiazide use with lip and cutaneous malignancies, the limited nature of the epidemiologic evidence and the small magnitude of the observed associations, only gave enough evidence for IARC to classify these findings as a 2B effect (possibly carcinogenic to humans). Furthermore, there were no data from animal cancer bioassays on the carcinogenic effects of hydrochlorothiazide/UV light combination exposure. Several members of the IARC Monographs Vol. 108 Working Group (J Dunnick, NIEHS; F. Beland, NCTR; Y. Grosse, IARC; W. Jameson, Toxicology Consultant) felt that the results of a hydrochlorothiazide/UV (solar simulated light) cancer study using the HRA mouse model would add to the understanding of hydrochlorothiazide carcinogenic potential.

NTP Principles: not specified

Agents and Status

The following information relates to the specific agent and may include history from earlier or later nominations for this same agent.

CASRN: 58-93-5

Agent Name: Hydrochlorothiazide